<DOC>
	<DOCNO>NCT02124668</DOCNO>
	<brief_summary>The purpose study monitor safety enzalutamide patient progressive castration-resistant prostate cancer previously treat docetaxel-based chemotherapy .</brief_summary>
	<brief_title>A Study Monitor Safety Enzalutamide Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Subject histologically cytologically confirm adenocarcinoma prostate Subject ongoing androgen deprivation therapy gonadotropinreleasing hormone ( GnRH ) analogue ( agonist antagonist ) plan maintain throughout study period prior orchiectomy ( i.e. , surgical medical castration ) Subject least one prior chemotherapy regimen metastatic castrationresistant prostate cancer least one regimen contain docetaxel Subject progressive disease indication change antineoplastic regimen Subject know suspected brain metastasis Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Subject able swallow study drug comply study requirement There comparable satisfactory alternative therapy treat subject 's disease Subject agree participate another interventional study treatment Subject severe concurrent disease , infection , comorbidity would make subject inappropriate enrollment Subject 's absolute neutrophil count &lt; 1000/μL , platelet count &lt; 100,000/μL , hemoglobin &lt; 6.2 mmol/L ( &lt; 10 g/dL ) Subject 's total bilirubin ≥ 1.5 x upper limit normal ( ULN ) ( except subject document Gilbert 's disease ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5x ULN Subject 's estimate creatinine clearance le 30 mL/min Cockcroft Gault formula Subject albumin ≤ 30 g/L ( ≤ 3.0 g/dL ) Subject receive antiandrogen therapy ( e.g . bicalutamide ) , chemotherapy , biologic therapy prostate cancer ( bone target agent bisphosphonates denosumab , gonadotropinreleasing hormone ( GnRH ) analogue therapy , glucocorticoid allow ) within 4 week Day 1 Subject prior use abiraterone Subject prior use , participation clinical trial , investigational agent block androgen synthesis ( e.g . TAK700 ) target androgen receptor ( e.g . ARN509 , ODM201 ) Subject : 1 . A history seizure , include febrile seizure condition may predispose seizure include , limited underlie brain injury , stroke , primary brain tumor , brain metastasis , 2 . A history loss consciousness transient ischemic attack within 12 month Screening Subject clinical sign suggestive high imminent risk pathological fracture , spinal cord compression and/or cauda equina syndrome Subject significant cardiovascular disease Subject receive investigational therapy within 28 day 5 half life , whichever longer , prior Screening Subject undergone major surgery within 4 week prior Screening Subject show hypersensitivity reaction active pharmaceutical ingredient capsule component , include Labrasol , butylate hydroxyanisole , butylate hydroxytoluene Subject use plan use , 30 day prior enrollment end study , medication know low seizure threshold prolong QT interval</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Xtandi</keyword>
	<keyword>MDV3100</keyword>
	<keyword>Progressive Castration-Resistant Prostate Cancer</keyword>
	<keyword>Enzalutamide</keyword>
</DOC>